SCHEMBL27081627

SCHEMBL27081627

Cc1n[nH]c2ncc(CN3CCc4ccc(C(=O)Nc5cncc(C(F)(F)F)c5)cc43)cc12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ WNT1 P04628 1/20 0.42
▸ BRAF P15056 1/20 0.42
▸ DDR2 Q16832 11/20 0.42
▸ DDR1 Q08345 10/20 0.42
▸ ABL1 P00519 5/20 0.42
▸ BCR P11274 2/20 0.42
▸ NTRK1 P04629 3/20 0.40
▸ NTRK3 Q16288 3/20 0.40
▸ NTRK2 Q16620 3/20 0.40
▸ KDR P35968 3/20 0.40
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ KIT P10721 1/20 0.39
▸ HIF1A Q16665 1/20 0.38
▸ EPAS1 Q99814 1/20 0.38
▸ FGFR1 P11362 1/20 0.38
▸ PDGFRB P09619 1/20 0.38
▸ SCN10A Q9Y5Y9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29968231 1.00 WNT1 (0.42) WNT1BRAFDDR2DDR1ABL1
SCHEMBL29968090 0.88 DDR2 (0.56) DDR2DDR1ABL1BCRNTRK1
SCHEMBL27081787 0.88 DDR2 (0.56) DDR2DDR1ABL1BCRNTRK1
SCHEMBL29967389 0.88 DDR2 (0.51) BRAFDDR2DDR1ABL1BCR
SCHEMBL27081794 0.88 DDR2 (0.51) BRAFDDR2DDR1ABL1BCR
SCHEMBL29967998 0.87 DDR2 (0.45) DDR2DDR1ABL1BCRNTRK1
SCHEMBL27082011 0.87 DDR2 (0.45) DDR2DDR1ABL1BCRNTRK1
SCHEMBL27081377 0.86 DDR1 (0.56) DDR2DDR1ABL1BCRNTRK1
SCHEMBL29967917 0.86 DDR1 (0.56) DDR2DDR1ABL1BCRNTRK1
SCHEMBL29967965 0.85 DDR2 (0.39) BRAFDDR2DDR1ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP claimed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US claimed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP claimed
CN-117062812-A Indoline derivatives as DDR inhibitors 奇斯药制品公司 2023-11-14 — — CN claimed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 WNT1 2587/4885BRAF 799/4885DDR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback